Top Tweets for #HiF2
Congratulations to @KCPUTSW @UTSWHemeOnc investigators on their @CD_AACR paper https://t.co/iauTEQZM27 establishing a role for #HIF2 in PTHrP regulation and hypercalcemia in #renalcancer & @kaelin_lab in press @NatureMedicine.
Listening to some extraordinary researchers, including a @NobelPrize-winning scientist, Bill Kaelin, and the incredible @DrChoueiri here at the @DanaFarber #MedicalOncology Faculty Retreat. #HIF2 #VHL
#ASCO2025 Día 2️⃣ - #GU
#kidneycancer
La Dra. @DrRanaMcKay y su interesante update de inhibidores #HIF2 en escenario avanzado y adyuvante.
🎯 #LITESPARK trials
🔜 Nuevas fronteras en CCR: casdatifan
Powerful talk by @DrRanaMcKay with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium.
#ASCO25 @ASCO @ASCOPost @JCO_ASCO @neerajaiims @montypal @bergsa83 @GlopesMd @VivekSubbiah @OncoAlert @tompowles1 @OncBrothers @yekeduz_emre @ZiadBakouny @AminNassarMD @NazliDizman
HIF-2 targeting is the next frontier for RCC, as VHL loss drives its overactivity; belzutifan's promising LITESPARK-005 results signal a wave of new therapies. #RCC #HIF2 #KidneyCancer | @brian_rini
https://t.co/ivc0YgpJet
Proud to have contributed to this massive work from Silvia Martin Puig lab @SMART18617738 and led by Teresa Albendea 💪.
#Vascular #HIF2 Signalling prevents #Cardiomegaly, Alveolar congestion, and Capillary Remodelling During Chronic #Hypoxia.
HIF2 signaling is necessary for the stability of heart and lung microvasculature during chronic hypoxia, preventing cardiac dysfunction and pulmonary congestion.
https://t.co/3mShLgguQy
Interesting interplay between #microbiome & #HIF2 pathways. Any implications for #kidneycancer, perhaps in the context of #belzutifan therapy? Could the effect of R. torques extend beyond the gut? Food for thought (pun intended). @mzugman @ReginaBarCar @NazliDizman @yunroseli https://t.co/pgU0BWJRSw
Appreciate your support @neerajaiims! Eager to present this data & get feedback at #ASCO24. The world of #HIF2 inhibition is ever expanding - will be good to get perspective on how we can develop novel rational combinations.
@NazliDizman @ZeynepZengin @LuisMezaco @EbrahimiHedyeh @mzugman @ReginaBarCar @PauloBergerot @crisbergerot @TDorffOnc @arafflemd @AbhiTrip87 @WesleyYipMD @yunroseli @ASCO
Ab#4513 @ASCO #ASCO24 👉https://t.co/ojEKABhpCy👉Ph1 study of DFF332, a novel oral HIF2α inhibitor, in pts w/ aRCC #kidneycancer👉promising safety profile & no grade 4 TRAEs or hypoxia reported👇Congrats @montypal @AlbigesL for the oral abst @OncoAlert @urotoday @KidneyCancer
Congratulations to the team including Nizar @MDAndersonNews @brian_rini on first #siRNA #RCC phase 1 https://t.co/psbH7od9ms with @ArrowheadPharma #HIF2 siRNA building upon https://t.co/NXPPwD7cIW (PMID36190432) opening new field.
Outstanding Distinguished Lecture @FoxChaseCancer with Dr. Bill Kaelin @DanaFarber @NobelPrize!
Great Science, Great Advice & Amazing Impact Bench-to-Bedside targeting #VHL via #HIF2 targeting in Cancer and Disease
He also suggested all checkout the QR code.
@CeiFccc
2) RCC: a lot around #HIF2 this time:
LBA87 - Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC) – COI: presented by @DrChoueiri (LBA)
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp Hypoxia: From Basic Mechanisms to Emerging Therapies, this May in Killarney! https://t.co/Cyish4LqnW #KSHypoxia23
Register now for On Demand Access to @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May to explore emerging #HIF2 #Hypoxic research! https://t.co/t8YK92blNo #KSHypoxia23
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! #KSHypoxia23
https://t.co/3uFxMRbisa
![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoOhsgXsAAsBDJ.png)
![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoODg7WAAACYKV.png)
![DrChoueiri's tweet photo. 4/ For the results:
N=52 patients were allocated to cohort 2.
Median time from dose 1 ➡️ data cut-off (Feb 1 22) = 24.6 months
-ORR 31% [95CI 18·7–45·1] (16/52): 1 CR (2%) + 15PR (29%) with 92% CR/PR/SD!
-Median TTR = 3.2 months (shorter than single agent HIF-2 inh)
#HIF2 #VEGF https://t.co/H5l8qwBzWw](https://pbs.twimg.com/media/FsoOBpaWYAMYBW4.png)
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! #KSHypoxia23
https://t.co/3uFxMRbisa
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! https://t.co/NWtrodABJe #KSHypoxia23
Explore emerging #HIF2 #Hypoxic research with field leaders @KeystoneSymp #Hypoxia: Basic Mechanisms to Emerging Therapies, this May in Killarney Co. Kerry! https://t.co/Lcf9Bickeu #KSHypoxia23
Last Seen Hashtags on Sotwe
Something went wrong.